Calvo I, Antón J, López Robledillo JC, de Inocencio J, Gamir ML, Merino R, Lacruz L, Camacho M, Rua MJ, Bustabad S, Díaz Cordovés-Rego G. [Recommendations for the use of methotrexate in patients with juvenile idiopathic arthritis].
An Pediatr (Barc) 2015;
84:177.e1-8. [PMID:
26077957 DOI:
10.1016/j.anpedi.2015.05.005]
[Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2015] [Revised: 05/04/2015] [Accepted: 05/05/2015] [Indexed: 10/23/2022] Open
Abstract
OBJECTIVES
To develop a consensus document of recommendations for the use of methotrexate (MTX) in patients with juvenile idiopathic arthritis (JIA).
MATERIAL AND METHOD
A group of eleven experts proposed several clinical questions on the use of MTX in patients with JIA. A systematic review was conducted and the evidence and recommendations for each question were extracted. The results were discussed and validated by the experts in a work session to establish the final recommendations.
RESULTS
MTX is recommended as the first drug for inducing remission in JIA, and its indication should be made according to the clinical category of the patient. Prior to treatment, it is recommended to perform a complete blood count, including white cells, levels of liver enzymes, serum creatinine, and other analytical parameters according to specific risk factors. Treatment should be initiated with a dose of 10-15 mg/m(2)/week. In cases of uveitis or polyarthritis, an initial dose of 15 mg/m(2)/week should be considered. For a better bioavailability and tolerability, it is preferable to administer MTX parenterally if the dose is ≥15 mg/m(2)/week. It is necessary to periodically perform an analytical monitoring of the patient and to assess possible alterations in liver enzymes to make changes if necessary. Combinations with biological agents may be necessary, as well as the concomitant addition of folic or folinic acid.
CONCLUSIONS
This document describes the main recommendations for the appropriate use of MTX in JIA patients, according to scientific evidence and clinical experience.
Collapse